Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05782712 |
| Other study ID # |
09C130 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
October 4, 2021 |
| Est. completion date |
May 31, 2022 |
Study information
| Verified date |
February 2024 |
| Source |
Istituto Auxologico Italiano |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Until now, a barrier to the widespread evaluation of adenosine in clinical practice has been
the difficulty of obtaining rapid reliable measures. A rapid method has recently been
developed which consists of measuring adenosine concentration in whole blood instead of
plasma by means of Mass Spectrometry (LC-MS/MS). In this study adenosine plasma levels were
assessed in a larger unselected cohort of patients affected by non-cardiac syncope and
compared the results with healthy controls.
Description:
Rationale and aim Until now, a barrier to the widespread evaluation of adenosine in clinical
practice has been the difficulty of obtaining rapid reliable measures. Indeed, owing to its
short half-life in the blood, adenosine is not easy to sample and measure. At the time of
venepuncture, a stop solution - not commercially available - must be utilized in order to
inhibit the degradation of adenosine in body fluid. After plasma deproteinization, adenosine
concentration is evaluated by means of high-performance liquid chromatography.
A rapid method has recently been developed which consists of measuring adenosine
concentration in whole blood instead of plasma by means of Mass Spectrometry (LC-MS/MS). In
brief, whole blood is collected after finger puncture and a drop is deposited on a blot paper
(Whatman). After the extraction of adenosine by means of a mixture consisting of methanol and
internal standard, its concentration is measured by LC-MS/MS. This method is rapid, well
accepted by the patient, not expensive, and easily replicable. Comparison between the two
above-mentioned methods in 20 healthy subjects and in patients with vasovagal syncope has
shown an acceptable correlation, with a r=0.65 and p<0.01. The mean adenosine concentration
was significantly higher in vasovagal syncope patients than in controls (3.1 µM versus 0.60
µM, p<0.001). However, the above results need to be replicated in a larger sample of patients
and controls before the blot paper method of measurement of adenosine can replace the
standard method.
In this study denosine plasma levels was assessed in a larger unselected cohort of patients
affected by non-cardiac syncope and compared the results with healthy controls.
Study design The rapid method of adenosine dosage in whole blood was assessed in patients
with syncope and in controls. The study was performed in patients referred to Istituto
Auxologico Italiano. The blood sample was be shipped to the Laboratory of Biochemistry,
Timone Hospital 264 Rue Saint-Pierre, 13385 Marseille, France for analysis Syncope group:
patients referred to the Syncope Unit of Auxologico with a diagnosis of possible or certain
reflex syncope (class I diagnostic criteria of ESC guidelines) after exclusion of competing
diagnoses.
There syncope patients are subdivided in 3 predefined subgroups:
- Subgroup A) Patients with no prodromes or very short prodromes (5 sec), normal heart and
normal ECG
- Subgroup B) Patients with typical vasovagal features (orthostatic or emotional triggers,
long prodromes with signs and symptoms of autonomic activation, i.e, nausea, sweating,
dizziness, pallor)
- Subgroup C) Patients who do not belong to none of the above subgroups.
No syncope group: 1) Patients without a history of syncope, referred to Auxologico for other
reasons; these patients have absence of severe structural heart disease and other
comorbidities. 2) Healthy volunteers selected among personnel of Auxologico. The selection of
these patients will be made matching them to syncope cases by age and sex.
Blood samples collection Whole blood is collected using finger puncture followed by deposit a
drop of blood (20 μL) using finnpipette, on a blotting paper (Whatman 903 protein saver
cards™) and dried over night at room temperature to obtain dried blood spot (DBS).
Blood samples extraction Six millimeters of dried blood spot (DBS) are cut out followed by
extraction with mixture consisting of methanol (400 μl) and internal standard (50 μl) in 2 mL
microfuge tubes then mixed for 90 min at 45°C. After extraction, an aliquot of 350 μL are
transferred into a new 2-mL safe-lock tube and evaporated to dryness at 60°C under nitrogen,
150 μl of 0.1% formic acid in water are added and quickly vortexed before transferring into
an HPLC auto sampler vial.
Adenosine dosage After the extraction of adenosine by means of a mixture consisting of
methanol and internal standard, its concentration is measured by LC-MS/MS.
Samples are analyzed using a Shimadzu UFLC XR system consisting of two LC-20ADXR binary
pumps, a DGU-20A5R vacuum degasser, and a CT0-20AC thermostated column oven and a SIL-20ACXR
cooled auto sampler (Shimadzu, Marne la Vallee, France). The LC system was interfaced with an
ABSciex 4500 triple quadrupole mass spectrometer (Les Ulis, France) operating with an
electrospray ionization source (ESI) using nitrogen (purity: 99.99%). Ten microliters of the
extracted sample were injected onto a 2.1 × 100 mm, 3 μm AtlantisR T3 column, Waters
(Guyancourt, France). The starting mobile phase consisted of 3% methanol and 97% acidified
water (0.1% formic acid) with a flow of 0.7 ml/min for 3.5 min. Then, the gradient of
methanol was increased to 30% for 3 min. The column was re- equilibrated for 2 min to
starting conditions.
